First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
- Solomon, Benjamin J.
- Mok, Tony
- Kim, Dong-Wan
- Wu, Yi-Long
- Nakagawa, Kazuhiko
- Mekhail, Tarek
- Felip, Enriqueta
- Cappuzzo, Federico
- Paolini, Jolanda
- Usari, Tiziana
- Iyer, Shrividya
- Reisman, Arlene
- Wilner, Keith D.
- Tursi, Jennifer
- Blackhall, Fiona
- Boyer, M.
- Ganju, V.
- Hughes, B.
- Pavlakis, N.
- Solomon, B.
- Varma, S.
- Berghmans, T.
- Canon, J-L
- Demedts, I.
- Janssens, A.
- Louis, R.
- Pieters, T.
- Schallier, D.
- Surmont, V.
- da Silva, C. Maciel
- Ferreira, C-G Moreira
- Hirsh, V.
- Joy, A.
- Laberge, F.
- Morzycki, W.
- Wierzbicki, R.
- Han, B.
- Liu, X.
- Qin, S.
- Shi, Y.
- Wang, Y.
- Wu, G.
- Wu, Y-L
- Zhou, C.
- Ahvonen, J.
- Barlesi, F.
- Cadranel, J.
- Dansin, E.
- Fayette, J.
- Morere, J-F
- Moro-Sibilot, D.
- Pujol, J-L
- Quoix, E.
- Zalcman, G.
- Frickhofen, N.
- Schneider, C-P
- Wehler, T.
- Mok, T.
- So, P.
- Cuffe, S.
- Bearz, A.
- Boni, C.
- Cappuzzo, F.
- Cognetti, F.
- De Braud, F.
- De Pas, T.
- Galetta, D.
- Migliorino, M.
- Rocco, D.
- Scagliotti, G.
- Tagliaferri, P.
- Tiseo, M.
- Aoe, K.
- Hida, T.
- Kato, T.
- Kozuki, T.
- Nakagawa, K.
- Niho, S.
- Nishio, M.
- Nokihara, H.
- Satouchi, M.
- Seto, T.
- Takahashi, T.
- Ahn, J-S
- Kim, D-W
- Kim, S-W
- Berchem, G.
- Rodriguez, O. Arrieta
- Biesma, B.
- Dingemans, A-M
- Smit, E.
- Helland, A.
- Barata, F.
- Gorbunova, V.
- Manikhas, G.
- Orlov, S.
- Leong, S.
- Lim, H-L
- Soo, R.
- Tan, E-H
- Nosworthy, A.
- Villena, M. Codes
- Felip, E.
- Lopez, P. Garrido
- Casado, D. Isla
- Banaclocha, N. Martinez
- Aix, S. Ponce
- Aransay, N. Reguart
- Abreu, D. Rodriguez
- Perez, J. Trigo
- Gautschi, O.
- Pless, M.
- Zippelius, A.
- Chang, G-C
- Tsai, Y-H
- Shparyk, Y.
- Blackhall, F.
- Steele, N.
- Armenio, V.
- Dragnev, K.
- Dugan, M.
- Gadgeel, S.
- Gerber, D.
- Graziano, S.
- Gurubhagavatula, S.
- Horn, L.
- Jalal, S.
- Lauer, R.
- Mehra, R.
- Mekhail, T.
- Mirshahidi, H.
- Pakkala, S.
- Polikoff, J.
- Raftopoulos, H.
- Saleh, M.
- Salgia, R.
- Waqar, S.
DOIAbstract
BACKGROUND The efficacy of the ALK inhibitor crizotinib as compared with standard chemotherapy as first-line treatment for advanced ALK-positive non-small-cell lung cancer (NSCLC) is unknown. METHODS We conducted an open-label, phase 3 trial comparing crizotinib with chemotherapy in 343 patients with advanced ALK-positive nonsquamous NSCLC who had received no previous systemic treatment for advanced disease. Patients were randomly assigned to receive oral crizotinib at a dose of 250 mg twice daily or to receive intravenous chemotherapy (pemetrexed, 500 mg per square meter of body-surface area, plus either cisplatin, 75 mg per square meter, or carboplatin, target area under the curve of 5 to 6 mg per milliliter per minute) every 3 weeks for ...
_-_Foto_Giovanni_Dall'Orto%2C_6-Dec-2007-cropped.jpg%3Fwidth%3D300&w=3840&q=75)
Add to ORKG